Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
News
Immunotherapy Greatly Improves Survival for Infants with an Aggressive Form of Leukemia
These results mark a big step forward in the treatment of infants with this form of Acute Lymphoblastic Leukemia (ALL).
News
Visionaries of the Year: A Campaign Powered by People Imagining a World Without Blood Cancer and Taking Action
The Leukemia & Lymphoma Society's philanthropic competition dedicates 10 weeks to end blood cancer
Patient Education Webcasts
Spotlight On Acute Myeloid Leukemia (AML)
News
FDA Approves Therapy to Decrease Infection Risk Following Stem Cell Transplant
“This new treatment is a big step forward that may help improve patient outcomes,” said LLS Chief Scientific Officer Lee Greenberger, Ph.D. “LLS was o…
News
FDA Approves Treatment for Patients Newly Diagnosed with Most Common Lymphoma
“The FDA’s decision gives newly diagnosed patients with this aggressive form of lymphoma their first new treatment option in nearly two decades,” says…
Research
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
Planegg/Munich, Germany, April 4, 2023 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that enrollment is complete for MANIFEST-2, the ongoing …
Research
Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
BERKELEY, Calif., April 04, 2023 - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company,…
News
The Leukemia & Lymphoma Society Joins CancerX Inaugural Project
The Leukemia & Lymphoma Society (LLS) has joined on as a proud partner of CancerX’s inaugural project, “Advancing Digital Innovation to Improve Equit…
Research
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated R/R PTCL at the American Association for Cancer Research Annual Meeting
Heidelberg, Germany, April 16, 2023 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their in…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
